1. Home
  2. INKT vs GDTC Comparison

INKT vs GDTC Comparison

Compare INKT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INKT
  • GDTC
  • Stock Information
  • Founded
  • INKT 2017
  • GDTC 2018
  • Country
  • INKT United States
  • GDTC Singapore
  • Employees
  • INKT N/A
  • GDTC N/A
  • Industry
  • INKT Medicinal Chemicals and Botanical Products
  • GDTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • INKT Health Care
  • GDTC Health Care
  • Exchange
  • INKT Nasdaq
  • GDTC Nasdaq
  • Market Cap
  • INKT 43.0M
  • GDTC 29.4M
  • IPO Year
  • INKT 2021
  • GDTC 2023
  • Fundamental
  • Price
  • INKT $10.82
  • GDTC $2.69
  • Analyst Decision
  • INKT Strong Buy
  • GDTC Buy
  • Analyst Count
  • INKT 2
  • GDTC 1
  • Target Price
  • INKT $6.50
  • GDTC $5.00
  • AVG Volume (30 Days)
  • INKT 71.7K
  • GDTC 33.6K
  • Earning Date
  • INKT 03-20-2025
  • GDTC 01-01-0001
  • Dividend Yield
  • INKT N/A
  • GDTC N/A
  • EPS Growth
  • INKT N/A
  • GDTC N/A
  • EPS
  • INKT N/A
  • GDTC N/A
  • Revenue
  • INKT N/A
  • GDTC $330,254.00
  • Revenue This Year
  • INKT N/A
  • GDTC $14.71
  • Revenue Next Year
  • INKT N/A
  • GDTC N/A
  • P/E Ratio
  • INKT N/A
  • GDTC N/A
  • Revenue Growth
  • INKT N/A
  • GDTC N/A
  • 52 Week Low
  • INKT $4.56
  • GDTC $1.20
  • 52 Week High
  • INKT $19.00
  • GDTC $4.05
  • Technical
  • Relative Strength Index (RSI)
  • INKT 59.75
  • GDTC 55.89
  • Support Level
  • INKT $7.32
  • GDTC $2.35
  • Resistance Level
  • INKT $13.79
  • GDTC $2.94
  • Average True Range (ATR)
  • INKT 2.07
  • GDTC 0.24
  • MACD
  • INKT 0.28
  • GDTC 0.04
  • Stochastic Oscillator
  • INKT 71.94
  • GDTC 84.63

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: